You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 169 No. 2, January 26, 2009 TABLE OF CONTENTS
  Archives
  •  Online Features
  Commentary
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (5)
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Similar articles in this journal
 Topic Collections
 •Cardiovascular System, Other
 •Nutritional and Metabolic Disorders
 •Lipids and Lipid Disorders
 •Cardiovascular System
 •Statistics and Research Methods
 •Cardiovascular Disease/ Myocardial Infarction
 •Drug Therapy
 •Adverse Effects
 •Endocrine Diseases
 •Diabetes Mellitus
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The ACCORD Trial and Control of Blood Glucose Level in Type 2 Diabetes Mellitus

Time to Challenge Conventional Wisdom

Stephen Havas, MD, MPH, MS

Arch Intern Med. 2009;169(2):150-154.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The decision by the National Institutes of Health to discontinue the glucose-lowering portion of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial unexpectedly after 3.5 years because of an increased mortality rate in those randomized to intensive treatment of high blood glucose level led to numerous stories in the mass media noting how experts in the field were stunned by the findings.1 Yet the results of this trial were predictable. For almost 40 years, there has been evidence that intensive lowering of glucose levels in patients with type 2 diabetes mellitus (DM) can lead to significant harm and has limited benefits. This raises the question of why so many clinicians neglected the accumulating evidence of harm and thereby got the issue of treating type 2 DM so wrong. This Commentary will seek to provide some answers to that question and to provide lessons . . . [Full Text of this Article]

THE WORKING HYPOTHESIS FOR MOST CLINICIANS


MAJOR RANDOMIZED CONTROLLED TRIALS IN TYPE 2 DM
Glucose-Lowering Trials

Lipid- and BP-Lowering Trials


RCTs IN TYPE 1 DM

THE BASIS FOR THE WORKING HYPOTHESIS

LESSONS LEARNED
Lesson 1

Lesson 2

Lesson 3

Lesson 4


RECOMMENDATIONS

ADDENDUM

AUTHOR INFORMATION


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED LETTERS

Changing the Diabetes Treatment Paradigm
Ronald Hirsch
Arch Intern Med. 2009;169(13):1246.
EXTRACT | FULL TEXT  

Treatment of Type 2 Diabetes: One Extreme to Another
Sarfraz Zaidi
Arch Intern Med. 2009;169(13):1246-1247.
EXTRACT | FULL TEXT  

Treatment of Type 2 Diabetes: One Extreme to Another—Reply
Stephen Havas
Arch Intern Med. 2009;169(13):1247.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effects of a Mediterranean-Style Diet on the Need for Antihyperglycemic Drug Therapy in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Trial
Esposito et al.
ANN INTERN MED 2009;151:306-314.
ABSTRACT | FULL TEXT  

How Much Evidence Do We Need to Change Practices in Which We Firmly Believe?
JWatch General 2009;2009:1-1.
FULL TEXT  

Changing the Diabetes Treatment Paradigm
Hirsch
Arch Intern Med 2009;169:1246-1246.
FULL TEXT  

Treatment of Type 2 Diabetes: One Extreme to Another--Reply
Havas
Arch Intern Med 2009;169:1247-1247.
FULL TEXT  

Treatment of Type 2 Diabetes: One Extreme to Another
Zaidi
Arch Intern Med 2009;169:1246-1247.
FULL TEXT  

Tight control of blood glucose in long standing type 2 diabetes
Lehman and Krumholz
BMJ 2009;338:b800-b800.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.